EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease in Lean Individuals

Samuel J Martínez-Domínguez iD, Sandra García-Mateo, Carla J Gargallo-Puyuelo, Beatriz Gallego-Llera, Pilar Callau, Carolina Mendi, María Teresa Arroyo-Villarino, Miguel Ángel Simón-Marco, Javier Ampuero, Fernando Gomollón

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Samuel J Martínez-Domínguez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Lozano Blesa University Hospital, Zaragoza, Spain. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diputación General de Aragón.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite classical association between metabolic dysfunction–associated steatotic liver disease (MASLD) and obesity, there is increasing evidence on the development of MASLD in lean individuals. The aim of the study was to assess the prevalence and risk factors of MASLD and significant liver fibrosis in lean participants with inflammatory bowel disease (IBD).

Methods

This was a cross-sectional, case-control study including 300 lean cases with IBD and 80 lean controls without IBD, matched by sex and age. All participants underwent a liver ultrasound, transient elastography, and laboratory tests.

Results

The lean IBD group showed a significantly higher prevalence of MASLD compared with lean non-IBD group (21.3% vs 10%; P = .022), but no differences were observed in the prevalence of significant liver fibrosis (4.7% vs 0.0%; P = 1.000). No differences were found between the prevalence of MASLD in IBD and non-IBD participants who were overweight/obese (66.8% vs 70.8%; P = .442). In addition, the prevalence of MASLD was significantly higher in the overweight/obese IBD group compared with the lean IBD group (P < .001). IBD was an independent risk factor for MASLD in lean participants (odds ratio [OR], 2.71; 95% confidence interval [CI], 1.05-7.01; P = .04), after adjusting for classic metabolic risk factors and prior history of systemic steroid use. Nevertheless, no association between IBD related factors and MASLD was identified in lean IBD participants. When the overweight/obese and lean IBD groups with MASLD were compared, the overweight/obese IBD group with MASLD showed higher levels of the homeostatic model assessment of insulin resistance (OR, 1.49; 95% CI, 1.11-1.98; P = .007) and history of smoking (OR, 4.66; 95% CI, 1.17-18.49; P = .029).

Conclusions

MASLD prevalence was higher in the lean IBD group compared with lean non-IBD group, independent of classic metabolic risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesHumansMaleFemaleCase-Control StudiesRisk FactorsCross-Sectional StudiesAdultPrevalenceMiddle AgedObesityThinnessBody Mass IndexNon-alcoholic Fatty Liver DiseaseLiver Cirrhosis

Stichwörter der Autor:innen

Crohn’s diseaseinflammatory bowel diseaselean MASLDliver fibrosisulcerative colitis

Autor:innen und Institutionen

  • Department of Gastroenterology, Lozano Blesa University Hospital, Zaragoza, Spain.
  • Digestive Pathology Translational Research Group, Aragón Health Research Institute, Zaragoza, Spain.
  • Department of Medicine, School of Medicine, University of Zaragoza, Zaragoza, Spain.
  • Primary care center Delicias Sur, Zaragoza, Spain.
  • Primary care center Universitas, Zaragoza, Spain.
  • Department of Digestive Diseases, Virgen del Rocío University Hospital, Sevilla, Spain.

ORCID-Profile: Samuel J Martínez-Domínguez

Förderung

  • Diputación General de Aragón

Zitieren

APA

Martínez-Domínguez, S. J., García-Mateo, S., Gargallo-Puyuelo, C. J., Gallego-Llera, B., Callau, P., Mendi, C., Arroyo-Villarino, M. T., Simón-Marco, M. Á., Ampuero, J., & Gomollón, F. (2024). Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease in Lean Individuals. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad175

Vancouver

Martínez-Domínguez SJ, García-Mateo S, Gargallo-Puyuelo CJ, Gallego-Llera B, Callau P, Mendi C, et al. Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease in Lean Individuals. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad175

BibTeX
@article{MartnezDomnguez2024,
  author = {Martínez-Domínguez, Samuel J and García-Mateo, Sandra and Gargallo-Puyuelo, Carla J and Gallego-Llera, Beatriz and Callau, Pilar and Mendi, Carolina and Arroyo-Villarino, María Teresa and Simón-Marco, Miguel Ángel and Ampuero, Javier and Gomollón, Fernando},
  title = {Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease in Lean Individuals},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad175}
}
Kostenlos starten →